Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient safety organizations

This article was originally published in The Gray Sheet

Executive Summary

HHS on Nov. 21 finalized a 1regulation establishing patient safety organizations - third-party groups certified by the government to accept patient safety event information from health care practitioners on a confidential basis. Required by the Patient Safety and Quality Improvement Act of 2005, PSOs are intended to give practitioners a way to report events without fear that the information will be used against them in lawsuits or professional sanctions. They do not negate FDA adverse event reporting requirements for devices and drugs (2"The Gray Sheet" Feb. 18, 2008, p. 7)

You may also be interested in...



Proposed Reg Offers Doctors More Discreet Way To Report Adverse Events

A proposed federal rule could increase the number of adverse event reports available for public analysis

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments

Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs. 

UsernamePublicRestriction

Register

MT026828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel